# Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

> **NCT00625443** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 53 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Blinded (placebo)
- **DRUG:** Open Label (Avatrombopag tablets)
- **DRUG:** Blinded (Avatrombopoag tablets)

## Key facts

- **NCT ID:** NCT00625443
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-10
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625443, "Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00625443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*